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Abstract: The liver expresses tissue-nonspecific alkaline phosphatase (TNAP), which may participate
in the defense against bacterial components, in cell regulation as part of the purinome or in bile secre-
tion, among other roles. We aimed to study the role of TNAP in the development of hepatosteatosis.
TNAP+/− haplodeficient and wild type (WT) mice were fed a control diet (containing 10% fat w/w)
or the same diet deficient in methionine and choline (MCD diet). The MCD diet induced substantial
weight loss together with hepatic steatosis and increased alanine aminotransferase (ALT) plasma
levels, but no differences in IL-6, TNF, insulin or resistin. There were no substantial differences
between TNAP+/− and WT mice fed the MCD diet. In turn, TNAP+/− mice receiving the control diet
presented hepatic steatosis with alterations in metabolic parameters very similar to those induced
by the MCD diet. Nevertheless, no weight loss, increased ALT plasma levels or hypoglycemia
were observed. These mice also presented increased levels of liver TNF and systemic resistin and
glucagon compared to WT mice. The phenotype of TNAP+/− mice fed a standard diet was normal.
In conclusion, TNAP haplodeficiency induces steatosis comparable to that produced by a MCD diet
when fed a control diet.
Keywords: methionine and choline diet; metabolic syndrome; biliary acids; tissue non-specific
alkaline phosphatase; steatohepatitis
1. Introduction
Non-alcoholic fatty liver disease (NAFLD), defined by the accumulation of fat in the
liver in the absence of significant alcohol intake, encompasses a spectrum of liver diseases
that can be further characterized as either non-alcoholic fatty liver (NAFL) or non-alcoholic
steatohepatitis (NASH), based on the presence or absence of inflammation and liver cell
injury. Because of its high incidence/prevalence, and its possible progression to cirrhosis
and ultimately to hepatic cancer, NAFLD is increasingly attracting attention [1]. In addition,
there is a close link between metabolic syndrome and NAFLD [2].
Alkaline phosphatases are a group of isoenzymes that in humans include the intesti-
nal (IAP), tissue non-specific (TNAP), fetal and placental isoforms [3]. These enzymes
share substrates and a common mechanism of action. Among them, TNAP comprises
three isoforms (liver, bone and kidney), identical in their final sequence but differing in
their glycosylations. TNAP is a pleiotropic enzyme expressed in multiple cell types and
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tissues, including liver, bone, brain, intestine, lymphocytes, macrophages or neutrophils.
Multiple substrates, such as bacterial components (LPS), nucleotides, phosphorylcholine
(PC), phosphoryl-ethanolamine or pyridoxal-5′-phosphate, have been described for TNAP,
and as a consequence, it has a role in multiple systemic processes, including bone miner-
alization, vitamin B6 metabolism and neurogenesis [4]. Mutations in the encoding gene
ALPL are the cause of hypophosphatasia.
In recent years, TNAP has been shown to exert different anti-inflammatory effects
depending on its actions on the innate and adaptive immune system. Two main mech-
anisms of action have been described. An increase in the production of IL-6 and TNF
has been observed in neutrophils from heterozygous TNAP+/− mice stimulated with LPS,
indicating an anti-inflammatory effect of the enzyme, possibly dependent on LPS dephos-
phorylation [5]. Another mechanism for TNAP to influence inflammation is the regulation
of purinergic signaling. In this regard, a recent study shows that TNAP inhibition in
neutrophils significantly exacerbates ATP-associated activation and secretion of IL-1β [6].
We have shown that TNAP is required for T cell activation and TNAP+/− T cells exhibit a
decreased colitogenic potential in vivo [7].
NAFLD and other features of metabolic syndrome, including obesity or diabetes,
are linked to subclinical inflammation, induced by alterations in the intestinal barrier,
resulting in increased levels of circulating bacterial antigens. Several studies have shown
the association of IAP with metabolic syndrome. In this regard, the administration of IAP to
mice fed a high-fat diet prevents endotoxemia and the associated metabolic syndrome [8],
while Akp3 (duodenal AP) knock-out mice show faster weight gain [9], visceral fat accu-
mulation and hepatic steatosis, as well as insulin resistance. Similarly, IAP deficiency has
been related to a higher lipid absorption in animals fed a high-fat diet [8]. The effects of
IAP on metabolic syndrome have been attributed to its ability to dephosphorylate LPS
and possibly other bacterial molecules. Since TNAP shares anti-inflammatory actions and
mechanisms with IAP and is involved in purinergic signaling, we hypothesized that it
could have a role in preventing hepatosteatosis. TNAP KO mice are only viable for a few
days; they die before weaning and show vitamin B6-sensitive epilepsy and impaired bone
mineralization. TNAP+/− haplodeficient mice are, however, viable, although they exhibit
an altered immune phenotype as noted.
TNAP is also known to dephosphorylate PC, to obtain choline to be absorbed in the
intestine, and is needed for the synthesis of phospholipids, acetylcholine and trimethyl-
glycine. Choline deficiency inhibits the synthesis of phosphatidylcholine required for
very low-density lipoprotein (VLDL) production and induces lipid accumulation in the
liver [10,11]. Here we explore the effect of the absence of an allele of TNAP (i.e., TNAP
haplodeficiency) on the development of fatty liver by methionine- and choline-deficient
diet (MCD) with a 10% w/w content of fat (22.1% Kcal from fat). In turn, the deficiency of
methionine decreases the biosynthesis of glutathione, leading to oxidative stress, which in
turn contributes to liver damage [12]. We found that TNAP+/− responded to the MCD diet
just like WT mice but developed fatty liver with the control diet, underscoring a role of
TNAP in the susceptibility to this dietary challenge.
2. Results
2.1. The Absence of a Single Alpl Allele Does Not Modify the Response of Mice to the MCD Diet
As expected, feeding the MCD diet resulted in sustained body weight loss in wild-type
mice for up to 17 days, when the experiment was halted for ethical reasons, as MCD-fed
mice had lost more than 20% of their body weight (Figure 1A). At this time, the expected
development of fatty liver was confirmed, as shown by steatosis (Figure 1B,C) and increased
alanine aminotransferase (ALT) circulating levels (Figure 1D). Nevertheless, no alteration
in the expression of pannexin 1 (Panx1, recently related to inflammation in non-alcoholic
steatohepatitis and to liver damage [13]) or the fibrosis markers transforming growth factor
β1 (Tgfb1) or desmin (Des) was observed (Figure 2). Accordingly, no hepatic inflammation
was shown, since liver mRNA levels of IL-1β (Il1b), IL-6 (Il6), TNF (Tnf ) and osteopontin
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(Spp1) were comparable to those of WT mice fed the control diet (Figure 2). The hepatic
expression of other inflammation-related markers, LPS binding protein (Lbp), Cd14 or
glutathione peroxidase 1 (GPx1), was also unchanged (Figure 2). Interestingly, alkaline
phosphatase activity and its sensitivity to levamisole were increased in WT mice fed the
MCD diet, consistent with a change in isoform (Figure 3). In general, these results indicate










Figure  2. Hepatic  expression  of  fibrosis  and  inflammatory  genes  in wild‐type  (WT)  and  TNAP  heterozygous mice 
(TNAP+/−) a control diet (10% w/w fat, control) or the same diet deficient in choline and methionine (MCD). Fold change of 
qRT‐PCR data are shown. + p < 0.05. 
Figure 1. Main parameters of the methionine- and choline-deficient diet (MCD) model. Body weight evolution (A),
liver histology (B), fat liver content (C), plasma ALT activity (D), glucose concentration in plasma (E) and HOMA-IR index
(F) of wild type (WT) and TNAP heterozygous mice (TNAP+/−) fed a control diet (10% w/w fat, control) or the same diet
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Figure 2. Hepatic expression of fibrosis and inflammatory genes in wild-type (WT) and TNAP heterozygous mice (TNAP+/−)
a control diet (10% w/w fat, control) or the ame diet deficient in choline and m thionine (MCD). Fold change of qRT-PCR
data are shown. + p < 0.05.











Figure 3. Hepatic alkaline phosphatase expression (A), activity (B) and sensitivity to levamisole (C)
of wild-type (WT) and TNAP heterozygous mice (TNAP+/−) fed a control diet (10% w/w fat, control)
or the same diet deficient in choline and methionine (MCD). For AP expression, fold change qRT-PCR
data are shown. + p < 0.05.
Glucidic metabolism genes were also assessed. No changes in the expression of
glucose-6-phosphatase catalytic subunit (G6pc) or glucose transporter 2 (Glut2) were ob-
served in WT mice fed the MCD diet, while a deep inhibition of liver phosphoenolpyruvate
carboxykinase 1 (Pck1), the key gluconeogenic enzyme, as well as induction of pyruvate
dehydrogenase kinase 4 (Pdk4), were noted (Figure 4). Pyruvate dehydrogenase kinase 4













Figure 4. Hepatic expression of glucidic and lipidic metabolism genes in wild-type (WT) and TNAP heterozygous mice
(TNAP+/−) fed a control diet (10% w/w fat, control) or th same diet deficient in choline and methionine (MCD). Fold chang
of qRT-PCR ta are shown. + p < 0.05.
When liver fatty acid metabolism was studied, the expression of key enzymes in
fatty acid synthesis, namely acetyl-CoA carboxylase (Acaca) and fatty acid synthase (Fasn),
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of the transcription factor steroid regulatory element-binding protein 1 (Srebf1), and of
fatty acid desaturase genes (Scd1, Fads1 or Fads2), was unchanged (Figure 4). Nevertheless,
an almost significant decrease in Tff3 (p = 0.056), recently described as a regulator of lipid
metabolism [14], was observed (Figure 4).
The MCD diet induced hypoglycemia with no change in insulin levels; therefore,
the HOMA-IR index was not affected (Figures 1E and 5). Plasma levels of leptin, IL-6,
C-peptide, ghrelin, gastric inhibitory peptide (GIP), pancreatic peptide (PP), peptide YY
(PYY), resistin and amylin were also unchanged (Figure 5). Only the levels of glucagon-like
peptide 1 (GLP-1) were shown to be increased, while those of glucagon were reduced,
































Plasma ALT activity and Panx1 mRNA  level were similar  to  those of WT mice  fed  the 
Figure 5. Plasma concentration of inflammation-, obesity- and steatosis-related markers in wild-type (WT) and TNAP
heterozygous mice (TNAP+/−) fed a control diet (10% w/w fat, control) or the same diet deficient in choline and methionine
(MCD). Results from the Metabolic H rm ne Expanded Panel multiplex are shown. + p < 0.05.
The assessment of intestinal parameters showed that weight-to-length ratio was
decreased in the colon, ileum and jejunum. Neither alkaline phosphatase activity nor
the expression of Alpl (encoding TNAP) were altered by the administration of the MCD
diet (Figure S1A/B). Only, as described in liver, sensitivity to levamisole was augmented.
Intestinal inflammatory or tight junction genes such as S100a8, Cldn4 and Tjp1 remained
unchanged (Figure S1C/D).
The effects of the MCD diet on TNAP+/− mice were very similar to those on wild
type mice, and the phenotypes were almost indistinguishable. The exception to this rule
was the increased levels of resistin and an almost significant increase in GIP (p = 0.06)
in the plasma of TNAP+/− mice (Figure 5), plus the lower sensitivity to levamisole of
alkaline phosphatase both in the intestine and liver, which was very similar to that of
control-diet-fed groups (Figure 3C).
2.2. Alpl Haplodeficiency Induces Hepatic Fat Accumulation in Mice Fed a Control Diet
Somewhat unexpectedly, when fed the control diet, the phenotype of TNAP+/−
mice differed considerably from that of the WT group. Thus systemic levels of glucagon,
resistin, GLP-1 and PP were increased in the TNAP+/− group (Figure 5). Insulin and PYY
showed a similar pattern but without reaching significance. An almost significant systemic
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increase in IL-6 (p = 0.076) was also observed. Remarkably, liver fat was augmented in
TNAP haplodeficient mice and was comparable to that of MCD-diet-fed animals of both
genotypes (Figure 1). However, steatosis presented with microdeposits at the histological
level, while larger fat deposits were observed in mice given the MCD diet with either
genotype (Figure 1B). In turn, there was no change in body weight, fasting blood glucose,
insulin or HOMA index, although values tended to be higher in TNAP+/− mice in the
latter case (Figures 1 and 5).
This phenotype was not anticipated, since TNAP+/− mice show no obvious phenotype
at the hepatic level, or indeed globally, in basal conditions. Since the control diet used
includes a higher-than-normal fat content, we decided to analyze the hepatic status under
standard feeding conditions, i.e., using a regular chow diet. In these conditions, no steatosis
was observed (Figure S2A), indicating that the interaction between genotype and the control
diet is responsible for the observed phenotype.
2.3. Characterization of Steatosis in Alpl Haplodeficient Mice
In addition to steatosis, RT-qPCR analysis revealed an increased expression of hepatic
Il1b and an almost significant increase in Tnf (p = 0.08). No other inflammation-related
genes were affected (Il6, Lbp, Cd14, Spp1 or Gpx1) (Figure 2). In turn, desmin gene expression
was increased in the liver of haplodeficient mice, consistent with possible fibrosis, and Tgfb
expression exhibited a very similar pattern, without reaching significance. Plasma ALT
activity and Panx1 mRNA level were similar to those of WT mice fed the same diet
(Figures 1D and 2). Taken together, these results are consistent with mild inflammation
with no substantial hepatic injury.
Next, the expression of key genes involved in hepatic glucidic and fatty acid metabolism
was studied using RT-qPCR. As in the mice fed the MCD diet, Pck1 and Tff3 expression
were significantly and profoundly decreased (Figure 4). We next looked at the expres-
sion of acyl-Coenzyme A synthetases and acyl-CoA thioesterases, which regulate fatty
acid metabolism, namely Acsm2, encoding mitochondrial acyl-coenzyme A synthetase,
and Acot5, encoding an acyl-coenzyme A thioesterase (Figure 6). The expression of Acsm2
was substantially decreased in the liver of mice fed the MCD diet, but also in haplodeficient
mice fed the control diet, and to a similar extent. In turn, Acot5 was strongly upregulated
solely in TNAP+/− mice on the control diet (26-fold, Figure 6). We additionally measured
the hepatic expression of hydroxy-delta-5-steroid dehydrogenase (Hds3b5), which is in-
volved in steroid metabolism and has been found to be downregulated in steatosis. Hds3b5
was virtually suppressed in TNAP+/− fed the control diet and the MCD diet (Figure 6).
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TNAP has been related to bile acid (BA) homeostasis [15]. Since steatosis has been
associated with induction of the acidic BA synthetic pathway, we studied the expression of
STAR (Star), 25-hydroxycholesterol 7-alpha-hydroxylase (Cyp7b1) and sulfotransferases 2a1
and 3a1 (Sulf2a1 and Sulf3a1). STAR (Steroidogenic Acute Regulatory Protein) regulates
the first, rate-limiting step in the acidic BA synthetic pathway, generating oxysterols,
while CYP7B1 is involved in the next step, which ultimately leads for the most part to
the generation of deoxycholic acid [16]. The sulfotransferases in turn are involved in BA
conjugation. Star was dramatically upregulated in all four groups receiving either the
control diet or the MCD diet, more so in the latter (Figure 6 and Figure S2A). We observed
a practically total suppression of Cyp7b1 expression in TNAP+/− vs. WT mice fed the
control diet, comparable to that measured in WT and haplodeficient mice fed the MCD diet
(Figure 6). Interestingly, our data also show augmented sulfation of BA, based on marked
upregulation of Sulf2a1 and Sulf3a1, in haplodeficient mice. Notably, this profile was found
to be identical in TNAP+/− mice fed the MCD diet (Figure 6).
No differences in the expression of genes involved in the synthesis of fatty acyl-CoA
or bile acid metabolism were observed in mice fed the control vs. the chow diet, indicating
that the alterations are due to a genotype:diet interaction (Figure S2B).
2.4. Alpl Haplodeficient Mice Exhibit a Reduced Activation of the AMPK but Not the AKT or the
PPARα Pathway
Because AMPK and AKT phosphorylation and the levels of PPARα have been re-
lated to hepatic steatosis, Western blot analysis was carried out with liver samples of WT
and TNAP haplodeficient mice fed the MCD or the control diet (Figure 7). A decreased
phosphorylated to total AMPK immunoreactivity ratio was observed globally in the liver
of haplodeficient mice (ANOVA p < 0.05 TNAP+/− vs. WT mice irrespective of diet).



































As  expected,  hypoglycemia was  also  observed, without  glucose  intolerance  [19].  The 
Figure 7. Hepatic ratio of p-AMPK to AMPK, p-AKT to AKT and PPARα to actin in wild type (WT)
and TNAP heterozygous mice (TNAP+/−) fed a control diet (10% w/w fat, control) or the same diet
deficient in choline and methionine (MCD). Western blot was used to analyze these parameters.
(A) Western blot images. (B) Quantification.
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3. Discussion
The development of NAFLD has been connected to an increase in intestinal perme-
ability that results in endotoxemia, inflammation and a higher fat accumulation in the
liver. It has been shown that the administration of a form of alkaline phosphatase, IAP,
to mice fed a high fat diet prevents the development of metabolic syndrome and the as-
sociated liver damage and steatosis [8]. These effects have been related to its inhibitory
effects on fat absorption and endotoxemia [9]. Here, we studied the effect of systemic
TNAP haplodeficiency in the development of NAFLD using the MCD model. The latter
consists of the administration of a diet devoid of both methionine and choline, resulting in
reduced hepatic mitochondrial β-oxidation and compromised very low-density lipoprotein
(VLDL) synthesis [11]. Liver expression of TNAP in haplodeficient mice fed a chow diet
has been previously shown to be approximately 50% of WT animals at the mRNA level,
while AP activity is not substantially diminished, at least using p-nitrophenylphosphate
as substrate [7]. In turn, sensitivity to levamisole is altered, consistent with a shift in
the glycosylation pattern and therefore of isoform, presumably secondary to changes in
biosynthetic rate [17,18].
As previously described, mice fed the MCD diet lost weight progressively, an effect
related to increased fatty acid mobilization in extrahepatic tissues. In fact, our experiment
had to be discontinued after 17 days for ethical reasons, owing to excessive weight loss.
As expected, hypoglycemia was also observed, without glucose intolerance [19]. The MCD
diet induced significant fat accumulation in the liver, with no inflammation either locally
or at the systemic level. In addition, no intestinal inflammation or alterations in intestinal
permeability markers were observed. These data may be due to insufficient follow-up time,
as TNF mRNA was already augmented in the liver of MCD-diet-fed mice, albeit nonsignifi-
cantly. In fact, our data are consistent with the observation that the MCD diet develops
intestinal permeability changes after an initial phase of liver injury and TNF induction [20].
The MCD diet had very similar effects in WT and TNAP+/− mice. In turn, while WT
mice fed the control diet exhibited a normal phenotype, TNAP+/− mice unexpectedly
developed steatosis, which was actually comparable to that induced by the MCD diet (in
either WT or haplodeficient mice). Since no liver anomalies had been previously noted in
TNAP+/− mice, liver fat content of mice fed a chow diet (with a regular 4% fat content)
was measured. The results obtained confirmed that haplodeficient mice do not develop
steatohepatitis in these conditions, indicating that it results from the interaction of TNAP
haplodeficiency with the control diet.
Despite a similar degree of hepatic steatosis, several features were different between
the TNAP+/− mice fed the control diet of the MCD diet. Thus, the livers of the former
presented numerous very small lipid vesicles (i.e., microsteatosis), while the livers of
MCD fed mice had predominantly large lipid droplets (i.e., macrosteatosis). In addition,
ALT levels were increased only in MCD-fed mice, while hepatic Il1b gene expression was
upregulated exclusively in TNAP+/− mice fed the control diet (with Tnf closely following,
albeit nonsignificantly, as mentioned). Similarly, Des (and Tgfb1 nonsignificantly) was
increased in TNAP+/− control mice, pointing to augmented fibrosis. To gain further
insight on the features of liver steatosis induced by the control diet in TNAP-deficient mice,
we characterized basic genes involved in the glucidic and lipid metabolism. Data show an
expression profile akin to that in the MCD diet groups. Thus Pck1, encoding cytoplasmatic
PEPCK, the key enzyme in gluconeogenesis, was dramatically downregulated, consistent
with inhibition of the citric acid cycle and fatty acid accumulation [21]. In contrast to
other studies indicating a reduced expression of genes involved in fatty acid synthesis
and desaturation [22], we found no changes in Fadsn, Acaca, Scd1, Fads1 and Fads2 in any
of the groups. In order to participate in metabolic processes (oxidation and synthesis of
complex lipids), fatty acids are activated by reaction with CoA to form fatty acyl CoA.
This reaction is catalyzed by different fatty acid acyl-CoA synthetases, while acyl-CoA
thioesterases catalyze the deactivation of fatty acid acyl-CoA. The expression of Acsm2,
encoding mitochondrial acyl-coenzyme A synthetase for medium-chain fatty acids 2,
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which has been related to insulin resistance [23], was inhibited in the MCD diet groups
as well as in TNAP+/− control mice, while that of Acot5, encoding an acyl-coenzyme A
thioesterase, was enhanced only in TNAP+/− control mice. These data are consistent with
reduced fatty acid Acyl-CoA synthesis by MCD diet and TNAP haplodeficiency with a
control diet, resulting in their lipid accumulation, reinforced by enhanced deactivation of
fatty acid Acyl-CoA in TNAP+/−/control mice.
Moderate elevations of serum levels of TNAP and total BA are common in NAFLD/
NASH patients [24,25]. Steatosis is associated with induction of the acidic BA biosynthetic
pathway, which is normally subdued (<10%) [16]. In addition, TNAP is induced in cholesta-
sis, although the role of TNAP in BA homeostasis is poorly characterized [15]. Strong
induction of Star, which is considered the rate-limiting step in the acidic BA pathway,
was noted in all four groups receiving control/MCD diets. However, steatosis did not
develop in WT mice on a control diet. The acidic pathway has been shown to lead to a
smaller BA pool with increased hydrophilicity and lower cholesterol dietary absorption
and improved lipid homeostasis. However, the downregulation of Cyp7b1 in this pathway,
which is typically found in steatosis [26], results in the accumulation of oxysterol inter-
mediaries, which have important inflammatory and regulatory effects. Of note, Cyp7b1
expression was strongly and inversely correlated with steatosis in the control/MCD groups.
Interestingly, it was induced in WT mice on a control diet, suggesting a protective role in
this context. Cyp7b1 expression is negatively regulated by insulin resistance, which was
not present in our study, and also by BA stimulation of FXR [16]. The expression profile
was very similar in the case of Hsd3b5, which is involved in steroid metabolism and is
also downregulated in steatosis. Thus BA accumulation may be a common mechanism in
TNAP+/−/control diet and MCD mice.
Interestingly, the expression of the sulfotransferases Sult2a1 and Sult3a1 was induced
in TNAP haplodeficient mice fed a control diet, independently of choline and methion-
ine content, but not with a standard diet. Sulfation is a conjugation reaction catalyzed
by sulfotransferases whereby a sulfonate (SO3−) group is transferred from the universal
sulfonate donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to a substrate. BA sul-
fation is favored in cholestasis [27], and it increases renal and intestinal elimination of
BA. In mice, sulfation involves the C7 position, which is less prone to hydrolysis [28].
These data are consistent with enhancement of BA elimination by TNAP haplodeficiency,
a TNAP+/−/control-diet-specific effect that cannot be ascribed to modulation of the BA
acidic pathway, choline depletion or steatosis.
Our data therefore show that steatosis results from both methionine and choline
deficiency and from TNAP haplodeficiency when exposed to a control diet (Figure 8).
No changes were observed in mice fed the chow diet, indicating an interaction between
TNAP and the control diet. The phenotype is more severe in the former, probably because
the MCD diet produces peripheral fat mobilization, but there is clear overlap (i.e., TNAP+/−
mice are similar to WT mice). This suggests a possible common pathogenic mechanism.
In this regard, TNAP may play a role in choline absorption by dephosphorylation of
phosphocholine. It is possible therefore that choline deficiency may be generated in
TNAP haplodeficient mice. Another possibility is the disruption of transcellular lipid
transport as described for IAP KO mice in the intestine [9]. The fact that such a striking
phenotype results from the lack of a single allele is remarkable, particularly considering
that alkaline phosphatase activity is not significantly reduced in the liver of TNAP+/−
mice, as observed also in a previous study [7]. As these measurements have been carried
out using a standard technique with p-nitrophenylphoshate as substrate, it is possible that
activity varies with other substrates, due to changes in glycosylation, as stated above. It is
interesting that Alpl mRNA expression was upregulated in TNAP+/−/control diet mice
(despite the lack of one allele), whereas alkaline phosphatase activity was increased in both
MCD groups, with different sensitivities to levamisole. Taken together, these data point to
modulation of TNAP in the three steatotic groups, perhaps secondary to BA accumulation.
These mechanisms will need future confirmation.

































Figure 8. Hypothesis based on the findings of the study.
In conclusion, in this study, we have shown that the deficiency in TNAP associated
with a control diet containing 10% w/w of fat induces a steatogenic response similar to that
observed in MCD-fed WT animals, with increased inflammatory and fibrotic features and
specific alterations in BA excretion.
4. Materials and Methods
4.1. Animals and Experimental Design
C57BL/6 heterozygous male and female mice for Alpl (B6.129S7-Akp2tm1Sor/J,
referred to as TNAP+/− mice) and wild-type (WT) littermates as controls were used in the
study. Seven to nine i per group wer studied. Mice were maintained at th U it of
Animal Research (Bio edical Research Center, University of Gran da, Gran da, Spain) in
air-conditioned animal quarters with a 12 h light/dark cycle and specific pathogen-free
conditi s. A im ls were housed in Makrolon® cages (4–5 mice r cage, mal s and
females kept sep rately) and were given free ac ess to autoclaved tap water and food
(Harlan-Teklad 2014, Harlan Ibér ca, Barcelona, Sp in) until the first day of the study.
A imal status was mo itored daily for signs of pain or suffe ing. Predefined criteria for
euthanasia included major weight loss, l ck f movement and hud ling behavior (none
of the latter were detected). Mice were anesthetized with an intraperitoneal injection of a
ketamine/xylazine mixture prior to cardiac exsangui ation. All protocols were approved
by the Animal Welfare Committee of the University of Granada (registry number: CEEA
01/03/2017–029) and carried out according to the Guide for the Care and Use of Laboratory
Animals. This study complies with the requirements on reporting research detailed in the
ARRIVE guidelines.
WT and TNAP+/− mice were distributed randomly to receive the MCD or the con-
trol diet (see below). Thus a 2 × 2 design was followed. Treatment was not blinded.
Mice weights were recorded daily. Animals were fed ad libitum for 17 days, when weight
loss reached the ethical limit in the MCD groups.
4.2. Diets
The methionine- and choline-deficient diet (Ref. TD.90262) and the control diet (Ref.
TD.94149) were purchased from Envigo (Indianapolis, IN, USA). Composition is given in
Tables 1 and 2. In some measurements, samples obtained from previous experiments with
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chow-fed animals were used as a reference group. After a 12 h fast, mice were euthanized,
and plasma samples and liver tissue fragments were collected and stored at −80 ◦C.
Table 1. Composition of diets.
Control MCD Diet Chow Diet
Sucrose (g/kg) 455 455 445
Corn starch (g/kg) 200 200 200
Corn Oil (g/kg) 100 100 40
l-Methionine (g/kg) 8.2 - 8.2
Choline (g/kg) 1.4 - 1.4
Table 2. Elemental composition of MCD and control diets.
g/Kg Control Diet MCD Diet
Sucrose 443.597 455.294
Corn starch 198.783 200.0
Corn Oil 100.0 100.0
Cellulose 30.0 30.0
Mineral Mix, AIN-76 (170915) 35.0 35.0
Calcium Phosphate, dibasic 3.0 3.0
L-Alanine 3.5 3.5
L-Arginine HCl 12.1 12.1
L-Asparagine 6.0 6.0
L-Aspartic Acid 3.5 3.5
L-Cysteine 3.5 3.5
L-Glutamic Acid 40.0 40.0
Glycine 23.3 23.3
L-Histidine HCl, monohydrate 4.5 4.5
L-Isoleucine 8.2 8.2
L-Leucine 11.1 11.1









Vitamin Mix, Teklad (400600)
+ Choline dihydrogen citrate
10.0
(1.4) -
Vitamin Mix, w/o choline, A, D, E (83171) - 5.0
Vitamin E, DL-α tocopherol acetate (500 IU/g) - 0.242
Vitamin A Palmitate (500,000 IU/g) - 0.0396
Vitamin D3, cholecalciferol (500,000 IU/g) - 0.0044
Ethoxyquin, antioxidant 0.02 0.02
4.3. Histological Assessment
Liver tissue fragments were fixed in 4% paraformaldehyde and embedded in paraffin.
For histological evaluation, slides were stained with hematoxylin and eosin (H&E). Images
were taken and digitalized using a Leica DMI3000B microscope (Leica, Wetzlar, Germany)
equipped with a Leica DFC420 camera. Sections were scored blindly for fat-drops size
and frequency.
4.4. Plasmatic Parameters
Fasting plasma samples were assayed for alanine aminotransferase activity (Sigma-
Aldrich, San Luis, MO, USA) and glucose concentration. The glucose oxidase method
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was used. Plasmatic parameters were measured using Metabolic Hormone Expanded
Panel multiplex (ref. MMHE-44K, Merk Millipore, Burlington, MA, USA) according to








4.5. Alkaline Phosphatase Activity
Colonic and hepatic tissues were mechanically homogenized in HTAB (Hexade-
cyltrimethylammonium Bromide) buffer using a Bullet Blender (Next Advance, Averill
Park, NW, USA). Alkaline phosphatase activity was measured spectrophotometrically,
using 5.5 mM disodium nitrophenyl phosphate as substrate. Sensitivity to the specific
inhibitor levamisole was tested and expressed as inhibition percentage.
4.6. Hepatic Fat Content
Liver samples were homogenized in distilled water using an electric homogenizer
(Heidolph, Schwabach, Germany). Chloroform:methanol solution was added to the ho-
mogenates to a 1:1:1 mix that was vortexed and centrifuged at 1100 g/20 min/4 ◦C.
The organic phase was collected and dried under a stream of nitrogen. Dry extract was
weighed, and results were reported as mg fat per gram of liver.
4.7. RNA Isolation and Quantitative Reverse-Transcription Polymerase Chain Reaction
(RT-qPCR) Analysis
RNA was isolated using RNeasy MiniKit (Qiagen, CA, USA) following the manufac-
turer’s instructions. RNA quantity and integrity were assessed spectrophotometrically
with Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA). Total RNA was subjected
to reverse transcription (BioRad, Hercules, CA, USA), and resulting cDNA was subjected
to quantitative PCR (Promega, Madison, WI, USA). Primers used to amplify Srebf1, Fasn
and Acaca were predesign primers from MilliporeSigma (Madrid, Spain). Other primers
used, and also purchased from MilliporeSigma, are shown in Table S1.
4.8. Western Blot
Liver tissues were homogenized in lysis buffer (0.1% w/v SDS, 0.1% w/v sodium de-
oxycholate, 1% v/v Triton X-100 in PBS) with a protease inhibitor cocktail 1:200 (v/v) (P9599;
MilliporeSigma, Madrid, Spain) and a phosphatase inhibitor cocktail 1:100 (v/v) (SC-45045;
Santa Cruz Biotechnology, Dallas, TX, USA) using a Bullet Blender (Next Advance, Averill
Park, NW, USA). Homogenates were sonicated and centrifuged 12,000 g/10 min/4 ◦C.
After protein concentration was determined by the bicinchoninic acid assay [29], samples
were heated at 95 ◦C for 5 min in Laemmli sample buffer (BioRad, Hercules, CA, USA).
Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes.
Samples were immunoblotted using the primary antibodies rabbit anti-AKT (ref. 9272s,
Cell Signaling Technology, MA, USA), Ser473 rabbit anti-pAKT antibody (ref. 4060s, Cell
Signaling Technology, MA, USA), rabbit anti-AMPKα antibody (ref. 2532L, Cell Signaling
Technology, MA, USA), Thr172 rabbit anti-pAMPKα antibody (ref. 2535s, Cell Signaling
Technology, MA, USA), rabbit anti-PPARα antibody (ref. ab3484, Abcam, Cambridge, UK)
and mouse anti-actin (A5441, Sigma-Aldrich, San Luis, MO, USA) at 1:1000 dilution. After
incubation with a secondary antibody, bands were detected by ECL (PerkinElmer, Waltham,
MA, USA) and quantified using ImageJ (National Institutes of Health, USA).
4.9. Statistical Analysis
Samples were run at least in triplicate, and results were expressed as mean± standard
error of the mean (SEM). Differences among means were tested by two-way ANOVA and a
posteriori Tukey’s multiple comparisons test or Student’s t-test for pairwise comparisons.
Analyses were carried out with GraphPad Prism 7 software (GraphPad Software, San Diego
CA, USA). Significance was accepted at p ≤ 0.05.
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